These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11720677)

  • 41. [Detection of human epidermal growth factor receptor 2 gene in invasive breast cancer by fluorescence in situ hybridization and research of its association with tumor characteristics].
    Su J; Yang Y; Ma XL; You JF; DU J; Liu JY; Zheng J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Apr; 43(2):199-203. PubMed ID: 21503112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
    Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
    Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
    Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
    J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
    Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
    Gu M; Ghafari S; Zhao M
    Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
    Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
    Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.
    Fiche M; Avet-Loiseau H; Heymann MF; Moussaly F; Digabel C; Joubert M; Classe JM; Dravet F; Fumoleau P; Ross J; Maugard CM
    Int J Cancer; 1999 Oct; 84(5):511-5. PubMed ID: 10502729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of different immunostaining patterns in HercepTest interpretation and criteria for gene amplification as determined by fluorescence in situ hybridization.
    Acs G; Wang L; Raghunath PN; Salscheider MA; Zhang PJ
    Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):222-9. PubMed ID: 12966348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunocytochemistry and fluorescence in situ hybridization in HER-2/neu status in cell block preparations.
    Shin SJ; Chen B; Hyjek E; Vazquez M
    Acta Cytol; 2007; 51(4):552-7. PubMed ID: 17718120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
    Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Indications for treatment in invasive ductal carcinoma of the breast with Herceptin from the aspect of laboratory diagnosis--study of the ERBB-2 protein and determination of the number of copies of the ERBB2 gene. Review].
    Mrhalová M; Kodet R
    Cesk Patol; 2002; 38 Suppl 1():4-14. PubMed ID: 12677891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
    Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.
    Varshney D; Zhou YY; Geller SA; Alsabeh R
    Am J Clin Pathol; 2004 Jan; 121(1):70-7. PubMed ID: 14750243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
    Lara PN; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Kauderer C; Tichauer G; Twardowski P; Doroshow JH; Gandara DR
    Cancer; 2002 May; 94(10):2584-9. PubMed ID: 12173324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
    Mrhalova M; Kodet R
    J Cancer Res Clin Oncol; 2007 May; 133(5):321-9. PubMed ID: 17165026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.